Multifactorial risk factor intervention in patients with Type2 diabetes improves arginine bioavailability ratios

Diabetic Medicine

Volumn 29, Issue 10, 2012, Pages

  Tripolt, N J ^a   Meinitzer, A ^a   Eder, M ^a   Wascher, T C ^b   Pieber, T R ^a   Sourij, H ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b HANUSCH HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ARGININE; CITRULLINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORNITHINE; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; DIABETES CONTROL; DIABETIC PATIENT; DISEASE DURATION; FEMALE; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RISK FACTOR; RISK MANAGEMENT;

AGED; ANTICHOLESTEREMIC AGENTS; ARGININE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CHOLESTEROL, LDL; CITRULLINE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; ORNITHINE; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84866435571     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03743.x     Document Type: Article

References (16)

1. Haffner SJ, Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med 2003; 115: 6S-11S.
2. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type2 diabetes. N Engl J Med 2003; 348: 383-393.
5. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-1964.
6. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type2 diabetes (UKPDS35): prospective observational study. Br Med J 2000; 321: 405-412.
7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type2 diabetes. N Engl J Med 2008; 358: 580-591.
8. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-658.
9. Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. J Am Med Assoc 2005; 294: 81-90.
10. Romero MJ, Platt DH, Tawfik HE, Labazi M, El-Remessy AB, Bartoli M et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res 2008; 102: 95-102.
11. Tang WH, Wang Z, Cho L, Brennan DM, Hazen SL. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 2009; 53: 2061-2067.
12. Sourij H, Meinitzer A, Pilz S, Grammer TB, Winkelmann BR, Boehm BO et al. Arginine bioavailability ratios are associated with cardiovascular mortality in patients referred to coronary angiography. Atherosclerosis 2011; 218: 220-225.
13. Österreichische Diabetes Gesellschaft. Diabetes mellitus - guidelines for the practice. Revised and expanded 2007 edition. Wien Klin Wochenschr 2009; 121 (Suppl. 5:) S1-S87.
14. Schwarz EL, Roberts WL, Pasquali M. Analysis of plasma amino acids by HPLC with photodiode array and fluorescence detection. Clin Chim Acta 2005; 354: 83-90.
15. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB et al. Effects of intensive glucose lowering in type2 diabetes. N Engl J Med 2008; 358: 2545-2559.
16. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type2 diabetes. N Engl J Med 2008; 359: 1577-1589.